PRISMA harms checklist: improving harms reporting in systematic reviews
暂无分享,去创建一个
David Moher | Douglas G Altman | Su Golder | Yoon K Loke | Liliane Zorzela | Sunita Vohra | J. Ioannidis | P. Santaguida | D. Moher | S. Golder | D. Altman | S. Vohra | Y. Loke | Pasqualina Santaguida | L. Zorzela | John P Ioannidis | Liliane Zorzela
[1] Jonathan J Shuster,et al. Empirical vs natural weighting in random effects meta‐analysis , 2009, Statistics in medicine.
[2] Su Golder,et al. THE CONTRIBUTION OF DIFFERENT INFORMATION SOURCES FOR ADVERSE EFFECTS DATA , 2012, International Journal of Technology Assessment in Health Care.
[3] J. Ioannidis,et al. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone. , 2008, American heart journal.
[4] A. B. Hill,et al. "The Environment and Disease: Association or Causation?" (1965), by Austin Bradford Hill , 2017 .
[5] B. Guglielmo,et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? , 2010, Journal of hospital medicine.
[6] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[7] D. Altman,et al. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research , 2004, Canadian Medical Association Journal.
[8] P. Middleton,et al. Maternal adverse effects of different antenatal magnesium sulphate regimens for improving maternal and infant outcomes: a systematic review , 2013, BMC Pregnancy and Childbirth.
[9] Y. Loke,et al. Bi‐directional interaction between hypoglycaemia and cognitive impairment in elderly patients treated with glucose‐lowering agents: a systematic review and meta‐analysis , 2016, Diabetes, obesity & metabolism.
[10] D. Sargent,et al. Adverse-event rates: journals versus databases , 2007, The Lancet.
[11] Theo Stijnen,et al. Random effects meta‐analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data , 2010, Statistics in medicine.
[12] S. Golder,et al. Unpublished data can be of value in systematic reviews of adverse effects: methodological overview. , 2010, Journal of clinical epidemiology.
[13] A. B. Hill. The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.
[14] Sally Hopewell,et al. Reporting of adverse events in systematic reviews can be improved: survey results. , 2008, Journal of clinical epidemiology.
[15] David Moher,et al. Increasing value and reducing waste in biomedical research: who's listening? , 2016, The Lancet.
[16] Y. Loke,et al. If nothing happens, is everything all right? Distinguishing genuine reassurance from a false sense of security , 2015, Canadian Medical Association Journal.
[17] J. Gray,et al. Evidence-Based Healthcare: How to Make Health Policy and Management Decisions , 2001 .
[18] I. Olkin,et al. The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.
[19] John P A Ioannidis,et al. Availability of large-scale evidence on specific harms from systematic reviews of randomized trials. , 2004, The American journal of medicine.
[20] Su Golder,et al. Failure or success of electronic search strategies to identify adverse effects data. , 2012, Journal of the Medical Library Association : JMLA.
[21] Jonathan J Shuster,et al. Rebuttal to Carpenter et al. comments on ‘Fixed vs. random effects meta‐analysis in rare event studies: The rosiglitazone link with myocardial infarction and cardiac death’ , 2008 .
[22] John P A Ioannidis,et al. Reasons or excuses for avoiding meta-analysis in forest plots , 2008, BMJ : British Medical Journal.
[23] Katja Jasinskaja,et al. Elaboration and Explanation ⋆ , 2011 .
[24] Lisa Hartling,et al. Quality of reporting in systematic reviews of adverse events: systematic review , 2014, BMJ : British Medical Journal.
[25] Isabelle Boutron,et al. Reporting of safety results in published reports of randomized controlled trials. , 2009, Archives of internal medicine.
[26] David Moher,et al. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane reviewa , 2012, Systematic Reviews.
[27] T. Michele,et al. The safety of tiotropium--the FDA's conclusions. , 2010, The New England journal of medicine.
[28] M. Schulzer,et al. The effect of a bolus dose of etomidate on cortisol levels, mortality, and health services utilization: a systematic review. , 2010, Annals of emergency medicine.
[29] John P A Ioannidis,et al. Adverse events in randomized trials: neglected, restricted, distorted, and silenced. , 2009, Archives of internal medicine.
[30] T. Einarson,et al. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events , 2008, Annals of the rheumatic diseases.
[31] Sally Hopewell,et al. PRISMA for Abstracts: Reporting Systematic Reviews in Journal and Conference Abstracts , 2013, PLoS medicine.
[32] Douglas G Altman,et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews , 2010, BMJ : British Medical Journal.
[33] S. Golder,et al. Poor reporting and inadequate searches were apparent in systematic reviews of adverse effects. , 2008, Journal of clinical epidemiology.
[34] Y. Yazici. Some concerns about adverse event reporting in randomized clinical trials. , 2008, Bulletin of the NYU hospital for joint diseases.
[35] J. Ioannidis,et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.
[36] D. Altman,et al. Selective reporting bias of harm outcomes within studies: findings from a cohort of systematic reviews , 2014, BMJ : British Medical Journal.
[37] John P A Ioannidis,et al. Optimal type I and type II error pairs when the available sample size is fixed. , 2013, Journal of clinical epidemiology.
[38] Anne-Marie Bagnall,et al. Bmc Medical Research Methodology Open Access Assessing Harmful Effects in Systematic Reviews , 2022 .
[39] Sheena Derry,et al. BMC Clinical Pharmacology BioMed Central BMC 1 2001, Clinical Pharmacology , 2001 .
[40] E. Ernst,et al. Assessment of therapeutic safety in systematic reviews: literature review , 2001, BMJ : British Medical Journal.
[41] T. Einarson,et al. Long-Term Developmental Outcome of Children of Women with Epilepsy, Unexposed or Exposed Prenatally to Antiepileptic Drugs , 2010, Drug safety.
[42] S. Golder,et al. Dexamethasone and haemorrhage risk in paediatric tonsillectomy: a systematic review and meta-analysis. , 2014, British journal of anaesthesia.
[43] A. Idrovo,et al. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials , 2009, Clinical rehabilitation.
[44] J. Ioannidis,et al. Safety of Medical Interventions in Children Versus Adults , 2014, Pediatrics.
[45] D. Moher,et al. Guidance for Developers of Health Research Reporting Guidelines , 2010, PLoS medicine.
[46] S. Shakir,et al. Systematic reviews of adverse effects of drug interventions: a survey of their conduct and reporting quality , 2009, Pharmacoepidemiology and drug safety.
[47] S. Haque. Ethics approval This study was conducted with the approval of the East London and City Health Authority Ethic Committee. Provenance and peer review Not commissioned; externally peer reviewed. , 2011 .
[48] P. Shekelle,et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation , 2016, British Medical Journal.
[49] A. Hrõbjartsson,et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. , 2004, JAMA.
[50] S. Bangalore,et al. Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials , 2011, BMJ : British Medical Journal.
[51] P. Enright,et al. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[52] G. D. Dal Pan,et al. Reporting of meta-analyses of randomized controlled trials with a focus on drug safety: An empirical assessment , 2013, Clinical trials.
[53] Andrew Herxheimer,et al. Systematic reviews of adverse effects: framework for a structured approach , 2007, BMC medical research methodology.
[54] D. Moher,et al. Improving the reporting and usability of research studies , 2013, Canadian Journal of Anesthesia/Journal canadien d'anesthésie.
[55] K. Pilkington,et al. Complementary medicine and safety: a systematic investigation of design and reporting of systematic reviews. , 2012, Complementary therapies in medicine.
[56] Published Online. Biomedical research: increasing value, reducing waste , 2014 .
[57] J. Ioannidis,et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.
[58] Andrew Forbes,et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. , 2014, The Cochrane database of systematic reviews.
[59] S. Golder,et al. Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources , 2011, Therapeutic advances in drug safety.
[60] G. Hejblum,et al. A systematic review of adult admissions to ICUs related to adverse drug events , 2014, Critical Care.
[61] R. Chou,et al. Challenges in Systematic Reviews That Assess Treatment Harms , 2005, Annals of Internal Medicine.
[62] J. Ioannidis,et al. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. , 2001, JAMA.
[63] Alexander J Sutton,et al. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. , 2004, Statistics in medicine.
[64] D. Spiegelhalter,et al. Consensus development methods, and their use in clinical guideline development. , 1998, Health technology assessment.
[65] A. Sandgren,et al. Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review , 2013, PloS one.
[66] R. O’Neill,et al. Does Research Synthesis Have a Place in Drug Regulatory Policy? Synopsis of Issues: Assessment of Safety and Postmarketing Surveillance , 1996 .
[67] D. Sackett,et al. Choosing the best research design for each question , 1997, BMJ.
[68] Amy T. Wang,et al. Clinical review 1: Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. , 2010, The Journal of clinical endocrinology and metabolism.
[69] Su Golder,et al. Some improvements are apparent in identifying adverse effects in systematic reviews from 1994 to 2011. , 2013, Journal of clinical epidemiology.
[70] A. Colevas,et al. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] Ingram Olkin,et al. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta‐analysis with zero cells , 2009, Statistics in medicine.
[72] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[73] J. Aronson,et al. BMC Medical Research Methodology BioMed Central BMC 1 2001, Medical Research Methodology , 2001 .
[74] W. Prendiville,et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.
[75] David Moher,et al. Reducing waste from incomplete or unusable reports of biomedical research , 2014, The Lancet.
[76] J Hartley,et al. Clarifying the abstracts of systematic literature reviews. , 2000, Bulletin of the Medical Library Association.
[77] R. Chou,et al. Methodological shortcomings predicted lower harm estimates in one of two sets of studies of clinical interventions. , 2007, Journal of clinical epidemiology.
[78] Jonathan J Deeks,et al. Much ado about nothing: a comparison of the performance of meta‐analytical methods with rare events , 2007, Statistics in medicine.
[79] H. Gooszen,et al. Robustness Assessments Are Needed to Reduce Bias in Meta-Analyses That Include Zero-Event Randomized Trials , 2009, The American Journal of Gastroenterology.
[80] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[81] David Moher,et al. AHRQ series paper 4: assessing harms when comparing medical interventions: AHRQ and the effective health-care program. , 2010, Journal of clinical epidemiology.
[82] Yoon K Loke,et al. Drug safety assessment in clinical trials: methodological challenges and opportunities , 2012, Trials.
[83] R. O’Neill,et al. Does Research Synthesis Have a Place in Drug Regulatory Policy? Synopsis of Issues: Assessment of Efficacy and Drug Approval , 1996 .
[84] Sonal Singh,et al. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies , 2011, BMJ : British Medical Journal.
[85] S. Reichenbach,et al. Metamizole-Associated Adverse Events: A Systematic Review and Meta-Analysis , 2015, PloS one.
[86] S. Golder,et al. Bmc Medical Research Methodology Open Access Room for Improvement? a Survey of the Methods Used in Systematic Reviews of Adverse Effects , 2006 .